Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

NCT05556928 | Recruiting

• 1 other identifier: IRB-300005372
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 1

Brief Summary

The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.

Conditions

Multiple Myeloma; Amyloidosis; Plasma Cell Leukemia

Outcome Measures

Primary Outcomes (1)

• Create the CARE-Heme Registry

  To establish and maintain a well-annotated registry (to be called the 'CARE-Heme' Registry) of adults ≥50 years of age with a hematologic malignancy to improve our understanding of this vulnerable population.

  5 years

Secondary Outcomes (1)

• To administer a patient reported geriatric assessment and a brief objective physical assessment.

  5 years

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients ≥50 years of age with a diagnosis of any Hematologic Malignancy having an appointment at any participating UAB entity.

You may qualify if:

• Patients are ≥50 years of age.
• Patients have a biopsy proven diagnosis of Hematologic Malignancy (Multiple Myeloma, AL Amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic syndromes, Myeloproliferative Neoplasm, Acute/Chronic Myeloid Leukemia, Acute/Chronic Lymphoid Leukemia).
• Patients have appointments at UAB including if they are an inpatient or other clinic locations.

You may not qualify if:

• Individuals who are \<50 years old.

Sponsors & Collaborators

• University of Alabama at Birmingham: lead

Study Sites (1)

Kirklin Clinic of UAB Hospital

Birmingham, Alabama, 35294, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

The purpose of the biospecimen collection is to support future investigations aimed at looking at biomarkers of frailty and aging and other new-onset comorbidities.

MeSH Terms

Conditions

Multiple Myeloma; Amyloidosis; Leukemia, Plasma Cell

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases; Leukemia

Central Study Contacts

Landon Martin, BS

CONTACT

(205) 638-2120; landoncmartin@uabmc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 22, 2022
• First Posted: September 27, 2022
• Study Start: July 21, 2020
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: December 8, 2025

Record last verified: 2025-12

Locations

US (1)